精制消癥丸调控乳腺增生大鼠性激素及其受体表达

目的:探讨精制消癥丸对乳腺增生大鼠性激素水平及其受体表达的影响。方法:大鼠适应性喂养1周后,造成乳腺增生模型。取造模成功大鼠随机分为6组:即模型组,消乳散结组(0.9 g·kg^-1,制剂量),消癥丸组(2.7 g·kg^-1,8.1 g·kg^-1,生药量),精制消癥丸组(2.7 g·kg^-1,8.1 g·kg^-1,生药量),并以正常SD雌性未孕大鼠作为空白对照组。给药组连续给药3周,模型组及空白对照组给予相应的生理盐水。实验结束后,观察血清性激素水平、乳腺组织性激素相关受体mRNA和蛋白的表达情况。结果:模型组大鼠E₂、PRL水平明显升高,P水平明显下降,但对FSH、LH无明显影响;乳腺组织ER_α、PGR、PRLR mRNA和蛋白表达明显上调。给予精制消癥丸及消癥丸后,能明显降低模型大鼠血清E₂、PRL水平,升高P水平,下调ER_α、PGR、PRLR mRNA和蛋白表达水平。结论:精制消癥丸和消癥丸可通过调节性激素水平、下调性激素受体基因和蛋白表达而发挥抗乳腺增生的作用,且两者作用相当,这为优化制备工艺、提高质量标准、减少临床服用量提供了可靠的实验依据。

Regulation of expression of sex hormones and its receptors in rats with mammary hyperplasia by refined Xiao Zheng Wan

OBJECTIVE To investigate the regulating effects of refined Xiao Zheng Wan on expression of sex hormones and its receptors in rats with mammary hyperplasia.METHODS Female rats developed into mammary hyperplasia model after adaptively fed for 1 week were divided into 6 groups: the model group, Xiao Ru San Jie group (0.9 g·kg^-1), Xiao Zheng Wan groups (2.7 g·kg^-1,8.1 g·kg^-1) and refined Xiao Zheng Wan groups (2.7 g·kg^-1,8.1 g·kg^-1). Normal and non-pregnant female rats were used as blank controls. All rats were gavaged for 3 weeks, the model and control animals received corresponding saline solution. After 3 weeks, serum levels of sex hormones, the mRNA and proteins of mammary tissues were measured.RESULTS in animal models, serum levels of estradiol (E₂) and prolactin (PRL) significantly improved, serum level of progesterone (P) decreased. However, no significant influence was observed on the follicle stimulating hormone (FSH) and luteinizing hormone (LH). The mRNA and protein expression of ER_α, PGR and PRLR were also up regulated in mammary tissues. The refined Xiao Zheng Wan and Xiao Zheng Wan could significantly decrease the serum levels of E₂, PRL and improve P level, and down regulate mRNA and protein expression of ER_α, PGR and PRLR. CONCLUSION the refined Xiao Zheng Wan and Xiao Zheng Wan have significant effects in treating mammary hyperplasia by regulating sex hormone levels, and descending mRNA and protein expression. We also found the refined Xiao-zheng-wan and Xiao-zheng-wan have similar potency, which provides a reliable experimental basis for optimizing the preparation process, improving the quality standards and reducing clinical dose.